ICLR vs. TEM: ICON vs. Tempus AI Stock Comparison
How do ICON (ICLR) and Tempus AI (TEM) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
ICON (ICLR) and Tempus AI (TEM) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
ICON (ICLR) carries decades of public-market history since May 15, 1998, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the ICLR side.
| Profile Item | ICLR | TEM |
|---|---|---|
| Name | ICON plc | Tempus AI Inc Class A Common Stock |
| Country/Region | Ireland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 15.34 billion USD | 13.87 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | May 15, 1998 | June 14, 2024 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ICLR | TEM |
|---|---|---|
| Total Return (1Y) | 30.55% | 16.25% |
| Total Return (3Y, Annualized) | -6.05% | -- |
| Total Return (5Y, Annualized) | -5.40% | -- |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Tempus AI (TEM) carries a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, whereas ICON (ICLR) is closer to market-like at 1.17 — a noticeable difference in market-sensitivity profile.
| Metric | ICLR | TEM |
|---|---|---|
| Volatility (1Y, Annualized) | 68.62% | 76.08% |
| Beta (5Y) | 1.17 | 3.34 |
| Max Drawdown (5Y) | -76.87% | -59.76% |
| Avg. Volume (3M) | 943.50K | 7.20M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ICLR | TEM |
|---|---|---|
| Sharpe Ratio (1Y) | 0.38 | 0.16 |
| Sortino Ratio (1Y) | 0.52 | 0.26 |
Profitability
ROE (TTM)
Tempus AI (TEM) reports a negative ROE of -37.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile ICON (ICLR) reports 4.70%, ranking against industry peers normally.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70%
- Max
- 109.18%
- Q3
- 6.23%
- ICLR
- 4.70%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-37.55%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- TEM
- -37.55%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile ICON (ICLR) reports 5.26%, ranking against industry peers normally.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.26%
- Max
- 18.05%
- ICLR
- 5.26%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-12.54%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- TEM
- -12.54%
- Min
- -17.05%
Operating Margin (TTM)
Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile ICON (ICLR) reports 10.73%, ranking against industry peers normally.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.73%
- Max
- 83.12%
- Q3
- 14.77%
- ICLR
- 10.73%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-13.82%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- TEM
- -13.82%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ICLR | TEM |
|---|---|---|
| ROE (TTM) | 4.70% | -37.55% |
| ROA (TTM) | 0.85% | -7.36% |
| Net Margin (TTM) | 5.26% | -12.54% |
| Operating Margin (TTM) | 10.73% | -13.82% |
| Gross Margin (TTM) | 23.44% | 64.46% |
Growth
Revenue Growth
Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while ICON (ICLR) at 0.76% is closer to the peer norm — faster top-line expansion for TEM.
EPS Growth
Only one side can be read here: ICON (ICLR) reports EPS growth of -71.56%, ranked against its industry; Tempus AI (TEM) has no EPS growth figure this period.
Growth Metrics
| Metric | ICLR | TEM |
|---|---|---|
| Revenue Growth (YoY) | 0.76% | 83.41% |
| Revenue Growth (3Y CAGR) | 2.15% | 58.29% |
| EPS Growth (YoY) | -71.56% | -- |
| EPS Growth (3Y CAGR) | -23.82% | -- |
Financial Strength
Current Ratio (MRQ)
Tempus AI (TEM) at 2.61 keeps current ratio within its industry’s typical mid-range, while ICON (ICLR) at 1.32 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ICLR.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.32
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- ICLR
- 1.32
- Min
- 0.10
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.61
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- TEM
- 2.61
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
ICON (ICLR) at 0.38 is near its industry mid-range for debt-to-equity ratio, while Tempus AI (TEM) at 2.86 sits above its benchmark range, pointing to a heavier debt load relative to equity.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.38
- Max
- 1.42
- Q3
- 0.65
- ICLR
- 0.38
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.86
- TEM
- 2.86
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ICLR | TEM |
|---|---|---|
| Current Ratio (MRQ) | 1.32 | 2.61 |
| Debt / Equity (MRQ) | 0.38 | 2.86 |
| Net Debt / EBITDA | 5.55 | -- |
Dividends
Dividend Yield (TTM)
Neither ICON (ICLR) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ICLR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither ICON (ICLR) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ICLR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ICLR | TEM |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: ICON (ICLR) trades at 81.90 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
81.90
- Max
- 85.34
- ICLR
- 81.90
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- TEM
- --
P/S Ratio (TTM)
ICON (ICLR) at 1.86 sits in the cheaper P/S ratio quartile while Tempus AI (TEM) at 9.19 prices around its industry’s middle — ICLR costs less per dollar of sales, though read it alongside growth and margins.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.86
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- ICLR
- 1.86
- Min
- 0.01
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.19
- Max
- 58.18
- Q3
- 25.77
- TEM
- 9.19
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
ICON (ICLR) at 1.68 sits in the lower P/B ratio quartile relative to book while Tempus AI (TEM) at 27.66 prices above its industry range — a wide valuation gap against assets.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.68
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- ICLR
- 1.68
- Min
- -5.59
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.66
- TEM
- 27.66
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ICLR | TEM |
|---|---|---|
| P/E Ratio (TTM) | 81.90 | -- |
| P/S Ratio (TTM) | 1.86 | 9.19 |
| P/B Ratio (MRQ) | 1.68 | 27.66 |
| Free Cash Flow Yield (TTM) | 3.51% | 0.30% |